EyePoint Grants 137,000 Stock Options to New Employees

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Dec 16 2025

0mins

Should l Buy EYPT?

EyePoint announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 137,000 shares of EyePoint common stock to nine new employees. The stock options were granted on December 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $16.40 per share, the closing price of EyePoint's common stock on December 15, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint through the applicable vesting dates.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy EYPT?" and start using high-conviction signals backed by rigorous historical data.

EYPT

$13.3+Infinity%1D

Analyst Views on EYPT

Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.50 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 12.730

Low

20.00

Averages

31.50

High

43.00

Current: 12.730

Low

20.00

Averages

31.50

High

43.00

Mizuho

Graig Suvannavejh

Outperform

maintain

2025-12-09

Reason

Mizuho

Graig Suvannavejh

Price Target

AI Analysis

2025-12-09

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh notes that Ocular Therapeutix (OCUL) recently announced its intent to accelerate the approval timeline for its sustained-release tyrosine kinase inhibitor/TKI, Axpaxli, by submitting an NDA off its Phase 3 SOL-1 study. For EyePoint (EYPT), with its first Phase 3 LUGANO data for Duravyu expected in mid-2026, this potentially positions an Axpaxli approval ahead of that for Duravyu, in a scenario the firm previously haven't assumed. That said, in Mizuho's view, even if Ocular's more aggressive regulatory approach succeeds, the firm sees a number of issues for the company and its Axpaxli. With this in mind, and its greater comfort in EyePoint's more thorough Phase 3 approach for Duravyu, along with the strength of the prior Phase 2 Duravyu data, the firm sees minimal read-throughs for EyePoint and remains Outperform-rated on the stock.

Mizuho

Graig Suvannavejh

maintain

$33

2025-11-11

Reason

Mizuho

Graig Suvannavejh

Price Target

$33

2025-11-11

maintain

Reason

Mizuho analyst Graig Suvannavejh views the recent pullback in shares of EyePoint as a buying opportunity. The company's Q3 update was "fine," with no major changes for lead asset Duravyu, the analyst tells investors in a research note. The firm says Duravyu remains on track in its two Phase 3 programs. Mizuho recommends buying the stock with an Outperform rating and $33 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EYPT

Unlock Now

About EYPT

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

EYPT Options Trading Analysis and Strategies

5 days agoNASDAQ.COM

Put Option Appeal: The current bid for the $12.50 put option is $2.50, and if an investor sells this option, they commit to buying the stock at $12.50, effectively lowering their cost basis to $10.00, which is about a 4% discount from the current price of $13.03, making it attractive for those interested in EYPT shares.
Return Potential Analysis: Should the put option expire worthless, the investor would realize a 20% return on their cash commitment, equating to an annualized yield of 36.69%, highlighting the potential attractiveness of this strategy in the current market environment.
Call Option Returns: The $15.00 call option has a bid of $3.00, and if an investor buys EYPT shares at $13.03 and sells this call option, they could achieve a total return of 38.14% if the stock is called away at expiration, showcasing the high return potential of this strategy.
Volatility Comparison: The implied volatility for the put option is 149%, while for the call option it is 147%, compared to a trailing twelve-month actual volatility of 73%, indicating a high market expectation for future volatility in EYPT shares, which necessitates careful risk assessment by investors.

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

Dec 31 2025Benzinga

Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.

EyePoint CEO Jay Duker to Present at 2026 J.P. Morgan Healthcare Conference

Dec 17 2025Globenewswire

Key Conference Presentation: EyePoint, Inc. CEO Jay S. Duker will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the company's innovative advancements in retinal disease treatments, which is expected to attract investor interest and enhance corporate visibility.
Clinical Trial Progress: EyePoint's lead product DURAVYU™ is currently undergoing Phase 3 pivotal trials, with topline data expected in mid-2026, which will provide crucial support for the company's future market launch and fundraising efforts.
Product Innovation: DURAVYU™ combines the selective tyrosine kinase inhibitor vorolanib with next-generation bioerodible Durasert E™ technology, aimed at improving the quality of life for patients with serious retinal diseases, demonstrating the company's technological edge in the biopharmaceutical sector.
Market Potential: EyePoint is committed to partnering with the retina community to drive long-term value creation, having approved four drugs over three decades and treated tens of thousands of eyes, indicating a strong foundation and future growth potential in the retinal disease treatment market.